This firm currently holds 298.74
M in liabilities with Debt to Equity (D/E) ratio of 2.4, implying Biocryst Pharma greatly relies on financing operations through barrowing. The company has a current ratio of 2.25, suggesting that it is liquid enough and is able to pay its financial obligations when due. Biocryst Pharma is UNDERVALUED at 15.72 per share with modest projections ahead.
We determine the current worth of BioCryst Pharmaceuticals using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of BioCryst Pharmaceuticals based exclusively on its
fundamental and basic
technical indicators. By analyzing BioCryst Pharmaceuticals's
financials, quarterly and monthly indicators, and related drivers such as
dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of BioCryst Pharmaceuticals's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of BioCryst Pharmaceuticals. We calculate exposure to BioCryst Pharmaceuticals's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to BioCryst Pharmaceuticals's related companies.
BioCryst Pharmaceuticals Investment Alerts
BioCryst investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring BioCryst Pharmaceuticals performance across your portfolios.Please check all
investment alerts for BioCryst
BioCryst Pharmaceuticals Valuation Ratios as Compared to Competition
Our valuation model uses many indicators to compare BioCryst value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BioCryst Pharmaceuticals competition to find
correlations between indicators driving the intrinsic value of BioCryst.
BioCryst Pharmaceuticals Gross Profit
BioCryst Pharmaceuticals Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing BioCryst Pharmaceuticals previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show BioCryst Pharmaceuticals Gross Profit growth over the last 10 years. Please check BioCryst Pharmaceuticals'
gross profit and other
fundamental indicators for more details.
A Deeper Perspective
The modest gains experienced by current holders of Biocryst Pharma could raise concerns from investors as the firm it trading at a share price of
14.78 on
15,031,827 in volume. The company directors and management have been quite successful in maneuvering the stock at opportune times to take advantage of all market conditions in
December. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.42. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Biocryst Pharma partners.
Margins Breakdown
Biocryst profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Biocryst Pharma itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Biocryst Pharma profit margins.
| Operating Margin | (101.42) |
| EBITDA Margin | (8.69) |
| Gross Margin | 0.84 |
| Profit Margin | (9.48) |
Biocryst Pharma Average Assets is increasing over the last 8 years. Moreover, Biocryst Pharma Earnings Before Interest Taxes and Depreciation Amortization USD is fairly stable at the moment.
Our perspective of the current Biocryst Pharma rise
Current kurtosis is at 5.3.
As of the 10th of January, Biocryst Pharma shows the
risk adjusted performance of
(0.022951), and Mean Deviation of 2.78. Biocryst Pharma
technical analysis gives you the methodology to make use of
historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of
historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for nineteen
technical drivers for Biocryst Pharma, which can be compared to its rivals. Please confirm
Biocryst Pharma coefficient of variation,
maximum drawdown, as well as the
relationship between the Maximum Drawdown and
skewness to decide if Biocryst Pharma is priced correctly, providing market reflects its regular price of 14.78 per share. Given that Biocryst Pharma has
jensen alpha of
(0.24), we suggest you to validate Biocryst Pharma's prevailing market performance to make sure the company can sustain itself at a future point.
Our Conclusion on Biocryst Pharma
While many of the other players under the biotechnology industry are still a bit expensive, Biocryst Pharma may offer a potential longer-term growth to investors. To conclude, as of the 10th of January 2022, our analysis shows that Biocryst Pharma almost mirrors the market. The company is
undervalued and projects
very high chance of distress for the next 2 years. Our current 90 days buy-or-sell advice on the company is
Hold.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of BioCryst Pharmaceuticals. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]
